[1]杨亚明,赵国安,冯春瑜,等.冠状动脉粥样硬化性心脏病患者的血脂代谢机制及药物治疗研究进展[J].新乡医学院学报,2021,38(10):996-1000.[doi:10.7683/xxyxyxb.2021.10.020]
点击复制

冠状动脉粥样硬化性心脏病患者的血脂代谢机制及药物治疗研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年10
页码:
996-1000
栏目:
综述
出版日期:
2021-10-05

文章信息/Info

作者:
杨亚明1; 赵国安1; 冯春瑜2; 林　飞1
（1.新乡医学院第一临床学院，河南　卫辉　453100；2.卫辉市人民医院内科三病区，河南　卫辉　453100）
关键词:
冠状动脉粥样硬化性心脏病; 脂质代谢; 胆固醇; 低密度脂蛋白
分类号:
R541.4
DOI:
10.7683/xxyxyxb.2021.10.020
文献标志码:
A
摘要:
血脂代谢紊乱是影响冠状动脉粥样硬化性心脏病（CAHD）发生、发展的重要危险因素。血脂由脂质和脂蛋白构成，乳糜微粒、胆固醇、三酰甘油、低密度脂蛋白、高密度脂蛋白、载脂蛋白B等脂质通过内源性、外源性和胆固醇逆转运3种转运途径进行代谢。血脂代谢途径的任何环节出现问题均会引发人体血脂水平紊乱，最终导致CAHD的发生和发展，而这些代谢途径也是药物干预的作用靶点。目前，前蛋白转化酶枯草杆菌蛋白酶-kexin9型抑制剂的发现为降低胆固醇水平开启了新的征程。本文旨在从血脂生物化学、脂质代谢、药物治疗等方面阐述CAHD的血脂代谢机制及其药物治疗研究进展。

参考文献/References:

［1］　MACH F,BAIGENT C,CATAPANO A L,et al.2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk［J］.Eur Heart J,2020,41(1):111-188.
［2］　HU S S,GAO R L,LIU L S,et al.(2019)Summary of the 2018 report on cardiovascular diseases in China［J］.Chin Circul J,2019,34(3):209-220.
［3］　DU X,PATEL A,ANDERSON C S,et al.Epidemiology of cardiovascular disease in China and opportunities for improvement:JACC international［J］.J Am Coll Cardiol,2019,73(24):3135-3147.
［4］　KOBIYANMA K,LEY K.Atherosclerosis［J］.Circ Res,2018,123(10):1118-1120.
［5］　WOLF D,LEY K.Immunity and inflammation in atherosclerosis［J］.Circ Res,2019,124(2):315-327.
［6］　史旭波,胡大一.有关胆固醇学说争议的简要回顾［J］.中国医刊,2014,49(5):25-26.
［7］　NICHOLLS M，MICHAEL S.Brown and Joseph L.Goldstein［J］.Eur Heart J,2019,40(42):3447-3449.
［8］　WIRKA R C,WAGH D,PAIK D T,et al.Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis［J］.Nat Med,2019,25(8):1280-1289.
［9］　LIBBY P,HANSSON G K.From focal lipid storage to systemic inflammation:JACC review topic of the week［J］.J Am Coll Cardiol,2019,74(12):1594-1607.
［10］　TABAS I,LICHTMAN A H.Monocyte-macrophages and T cells in atherosclerosis［J］.Immunity,2017,47(4):621-634.
［11］　MICHOS E D,MCEVOY J W,BLUMENTHAL R S,et al.Lipid management for the prevention of atherosclerotic cardiovascular disease［J］.N Engl J Med,2019,381(16):1557-1567.
［12］　ARNETT D K,BIUMENTHAL R S,ALBERT M A,et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease:a report of the american college of cardiology/American heart association task force on clinical practice guidelines［J］.Circulation,2019,140(11):e596-e646.
［13］　WILSON P W F,POLONSKY T S,MIEDEMA M D,et al.Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol［J］.J Am Coll Cardiol,2019,73(24):3210-3227.
［14］　SNIDERMAN A D,PENCINA M,THANASSOULIS G.ApoB［J］.Circ Res,2019,124(10):1425-1427.
［15］　TSIMIKAS S,KARWATOWSKA-PROKOPCZUK E,GOUNI-BERTHOLD I,et al.Lipoprotein(a) reduction in persons with cardiovascular disease［J］.N Engl J Med,2020,382(3):244-255.
［16］　TSIMIKAS S,MORIARTY P M,STROES E S.Emerging RNA therapeutics to lower blood levels of Lp(a):JACC focus seminar 2/4［J］.J Am Coll Cardiol,2021,77(12):1576-1589.
［17］　ROBINSON J G,STONE N J.The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk:a new paradigm supported by more evidence［J］.Eur Heart J,2015,36(31):2110-2118.
［18］　LLOYD-JONES D M,MORRIS P B,BALLANTYNE C M,et al.2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk:a report of the American college of cardiology task force on expert consensus decision pathways［J］.J Am Coll Cardiol,2017,70(14):1785-1822.
［19］　MILLS E J,RACHLIS B,WU P,et al.Primary prevention of cardiovascular mortality and events with statin treatments:a network meta-analysis involving more than 65,000 patients ［J］.J Am Coll Cardiol，2008,52(22):1769-1781.
［20］　FERENCE B A,GINSBERG H N,GRAHAM I,et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease.1.Evidence from genetic,epidemiologic,and clinical studies.A consensus statement from the European atherosclerosis society consensus panel［J］.Eur Heart J,2017,38(32):2459-2472.
［21］　EMERGING RISK FACTORS COLLABORATION,DI ANGELANTONIO E,GAO P,et al.Lipid-related markers and cardiovascular disease prediction［J］.JAMA,2012,307(23):2499-2506.
［22］　GREENLAND P,ALPERT J S,BELLER G A,et al.2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American college of cardiology foundation/American heart association task force on practice guidelines［J］.Circulation,2010,122(25):e584-e636.
［23］　GENEST J,MCPHERSON R,FROHLICH J,et al.2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations［J］.Can J Cardiol,2009,25(10):567-579.
［24］　KOPIN L,LOWENSTEIN C.Dyslipidemia［J］.Ann Intern Med,2017,167(11):ITC81-ITC96.
［25］　TEMEL R E,BROWN J M.A new model of reverse cholesterol transport:enTICEing strategies to stimulate intestinal cholesterol excretion［J］.Trends Pharmacol Sci,2015,36(7):440-451.
［26］　ROSENSON R S,BREWER H B,JR.,DAVIDSON W S,et al.Cholesterol efflux and atheroprotection:advancing the concept of reverse cholesterol transport［J］.Circulation,2012,125(15):1905-1919.
［27］　GUERIN M,SILVAIN J,GALL J,et al.Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction［J］.J Am Coll Cardiol,2018,72(25):3259-3269.
［28］　LANGSTED A,KAMSTRUP P R,NORDESTGAARD B G.High lipoprotein(a) and high risk of mortality［J］.Eur Heart J,2019,40(33):2760-2770.
［29］　VAN DER LAAN S W,HARSHFILELD E L,Hemerich D,et al.From lipid locus to drug target through human genomics［J］.Cardiovasc Res,2018,114(9):1258-1270.
［30］　FENG X,ZHANG L,XU S,et al.ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis:an updated review［J］.Prog Lipid Res,2020,77:101006.
［31］　DEFESCHE J C,GIDDING S S,HARADA-SHIBA M,et al.Familial hypercholesterolaemia［J］.Nat Rev Dis Primers,2017,3:17093.
［32］　COSTET P,KREMPF M,CARIOU B.PCSK9 and LDL cholesterol:unravelling the target to design the bullet［J］.Trends Biochem Sci,2008,33(9):426-434.
［33］　FERENCE B A,GRAHAM I,TOKGOZOGLU L,et al.Impact of lipids on cardiovascular health:JACC health promotion series［J］.J Am Coll Cardiol,2018,72(10):1141-1156.
［34］　LAUFS U,DESCAMPS O S,CATAPANO A L,et al.Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention［J］.Eur Heart J,2014,35(30):1996-2000.
［35］　SAEED A,FEOFANOVA E V,YU B,et al.Remnant-like particle cholesterol,low-density lipoprotein triglycerides,and incident cardiovascular disease［J］.J Am Coll Cardiol,2018,72(2):156-169.
［36］　ZHENG Y,LI T.Concept framework of vaccines-like administration to preatherosclerosis［J］.Circ Res,2019,124(4):488-490.
［37］　GOLDBERG I J,SHARMA G,FISHER E A.Atherosclerosis:making a U turn［J］.Annu Rev Med,2020,71:191-201.
［38］　MARSTON N A,KAMANU F K,NORDIO F,et al.Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score:results from the FOURIER trial［J］.Circulation,2020,141(8):616-623.
［39］　GOODMAN S G,STEG P G,SZAREK M,et al.Sustained low-density lipoprotein cholesterol lowering with alirocumab in ODYSSEY OUTCOMES［J］.J Am Coll Cardiol,2020,75(4):448-451.
［40］　GUEDENEY P,GIUSTINO G,SORRENTINO S,et al.Efficacy and safety of alirocumab and evolocumab:a systematic review and meta-analysis of randomized controlled trials［J］.Eur Heart J,2019，［online ahead of print］.DOI:10.1093/eurheartj/ehz430.
［41］　RAAL F J,KALLEND D,RAY K K,et al.Inclisiran for the treatment of heterozygous familial hypercholesterolemia［J］.N Engl J Med,2020,382(16):1520-1530.
［42］　RAY K K,WRIGHT R S,KALLEND D,et al.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol［J］.N Engl J Med,2020,382(16):1507-1519.
［43］　林润杰，魏锦坤，周丽红.冠心病患者血清循环PCSK9水平与脂代谢和颈动脉粥样硬化的关系分析［J］.中国循证心血管医学杂志,2019,11(6):684-687.
［44］　朱琪，贾海波，季梅丽.冠状动脉粥样硬化性心脏病患者血清前蛋白转化酶枯草溶菌素9、载脂蛋白M与冠状动脉病变程度的关系［J］.中国医刊,2021,56(10):1068-1071.
［45］　SEIDAH N G, PRAT A.The multifaceted biology of PCSK9［J］.Endocr Rev,2021.［online ahead of print］.DOI:10.1210/endrev/bnab035.
［46］　LAUFS U, FERENCE B A.Vaccination to prevent atherosclerotic cardiovascular diseases［J］.Eur Heart J,2017,38(32):2508-2510.
［47］　LANDLINGER C,POUWER M G,JUNO C,et al.The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol,vascular inflammation,and atherosclerosis in APOE*3Leiden.CETP mice［J］.Eur Heart J,2017,38(32):2499-2507.
［48］　CROSSEY E,AMAR M J A,SAMPSON M,et al.A cholesterol-lowering VLP vaccine that targets PCSK9［J］.Vaccine,2015,33(43):5747-5755.
［49］　HEGELE R A,TSIMIKAS S.Lipid-lowering agents targets beyond PCSK9［J］.Circ Res,2019,124(3):386-404.
［50］　KOLOVOU G,DIAKOUMAKOU O,KOLOVOU V,et al.Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia［J］.Eur J Prev Cardiol,2020,27(2):157-165.

相似文献/References:

[1]乔汉臣.非酒精性脂肪肝病研究进展[J].新乡医学院学报,2006,23(06):630.
[2]吕风华,张素荣,张跃光,等.冠状动脉粥样硬化性心脏病合并充血性心力衰竭患者血浆脑钠肽水平的检测[J].新乡医学院学报,2007,24(06):581.
[3]廖燕.老年冠状动脉粥样硬化性心脏病患者心功能与肺动脉压和心电指标的关系[J].新乡医学院学报,2012,29(09):696.
[4]郭鹏,李继红.不同类型冠状动脉粥样硬化性心脏病患者血浆D-二聚体和纤维蛋白原水平变化[J].新乡医学院学报,2012,29(09):698.
[5]李永锋,许志强,韩 鹏,等.冠状动脉粥样硬化性心脏病合并阻塞性睡眠呼吸暂停低通气综合征的临床分析 [J].新乡医学院学报,2012,29(10):784.
[6]舒　毅,陈幼萍,曾春平,等. ２型糖尿病合并冠状动脉粥样硬化性心脏病患者下肢血管病变相关因素分析[J].新乡医学院学报,2015,32(08):785.
[7]孙晓鹏,李辞霞,郭志坤.心肌脂肪酸代谢和心肌脂毒性损伤研究进展[J].新乡医学院学报,2018,35(7):646.[doi:10.7683/xxyxyxb.2018.07.025]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(10):646.[doi:10.7683/xxyxyxb.2018.07.025]
[8]许明发,王帅飞,苏国宝,等.不同血运重建方式治疗冠状动脉粥样硬化性心脏病合并左心室功能不全的早期疗效比较[J].新乡医学院学报,2018,35(11):1018.[doi:10.7683/xxyxyxb.2018.11.018]
　XU Ming-fa,WANG Shuai-fei,SU Guo-bao,et al.Comparison of early outcomes of two kinds of revascularization on the patients with coronary heart disease complicated with left ventricular dysfunction[J].Journal of Xinxiang Medical University,2018,35(10):1018.[doi:10.7683/xxyxyxb.2018.11.018]
[9]欧红萍,李 彬,周凤勤.颈动脉超声检查联合血清超敏C 反应蛋白水平检测在冠状动脉粥样硬化性心脏病诊断中的应用[J].新乡医学院学报,2014,31(10):825.[doi:10.7683/xxyxyxb.2014.10.016]
[10]王　一.冠状动脉粥样硬化性心脏病合并二尖瓣疾病和心房颤动患者同期行冠状动脉搭桥联合二尖瓣置换术和双极射频消融术疗效观察[J].新乡医学院学报,2019,36(2):155.[doi:10.7683/xxyxyxb.2019.02.013]
　WANG Yi.Clinical effect of coronary artery bypass grafting and mitral valve replacement and bipolar radiofrequency ablation on the patients with coronary atherosclerotic heart disease combined with mitral valve disease and atrial fibrillation[J].Journal of Xinxiang Medical University,2019,36(10):155.[doi:10.7683/xxyxyxb.2019.02.013]

更新日期/Last Update: 2021-10-05